AxoGen, Inc. (NASDAQ:AXGN) Short Interest Down 7.3% in December

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 1,010,000 shares, a drop of 7.3% from the November 30th total of 1,090,000 shares. Based on an average trading volume of 356,700 shares, the short-interest ratio is presently 2.8 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised AxoGen from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AxoGen currently has an average rating of "Buy" and a consensus price target of $15.00.

AxoGen Stock Performance

NASDAQ:AXGN traded down $0.01 during mid-day trading on Tuesday, reaching $16.48. 589,798 shares of the company's stock were exchanged, compared to its average volume of 392,300. AxoGen has a one year low of $5.55 and a one year high of $17.23. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The business's fifty day simple moving average is $14.25 and its two-hundred day simple moving average is $12.17. The firm has a market capitalization of $725.25 million, a PE ratio of -51.50 and a beta of 1.06.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AXGN. Quest Partners LLC grew its holdings in shares of AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 2,076 shares in the last quarter. nVerses Capital LLC acquired a new stake in AxoGen during the third quarter worth about $56,000. Koss Olinger Consulting LLC bought a new position in AxoGen in the 2nd quarter valued at about $75,000. Acadian Asset Management LLC acquired a new position in shares of AxoGen in the 2nd quarter valued at approximately $125,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of AxoGen during the 3rd quarter worth approximately $156,000. 80.29% of the stock is owned by institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.